01.29.19
Allergan
4Q Revenues: $4.1 billion (-6%)
4Q Loss: $4.3 billion (earnings were $3.1 billion 4Q17)
FY Revenues: $15.8 billion (-1%)
FY Loss: $5.1 billion (loss of $4.1 billion FY17)
Comments: Loss in the quarter was impacted by divestitures, products that lost exclusivity and a decline in RESTASIS (down 19% to $325 million) due to lower demand and net pricing, as well as the divestiture of the company's Medical Dermatology business in September 2018. BOTOX Therapeutic (Neurosciences & Urology) revenues in the quarter were $433.3 million, up 13%. U.S. General Medicine revenues in the quarter were $1.4 billion, down 8%, impacted by lower revenues from NAMENDA XR and ESTRACE due to generic competition, offset by growth from VRAYLAR and Lo LOESTRIN.
4Q Revenues: $4.1 billion (-6%)
4Q Loss: $4.3 billion (earnings were $3.1 billion 4Q17)
FY Revenues: $15.8 billion (-1%)
FY Loss: $5.1 billion (loss of $4.1 billion FY17)
Comments: Loss in the quarter was impacted by divestitures, products that lost exclusivity and a decline in RESTASIS (down 19% to $325 million) due to lower demand and net pricing, as well as the divestiture of the company's Medical Dermatology business in September 2018. BOTOX Therapeutic (Neurosciences & Urology) revenues in the quarter were $433.3 million, up 13%. U.S. General Medicine revenues in the quarter were $1.4 billion, down 8%, impacted by lower revenues from NAMENDA XR and ESTRACE due to generic competition, offset by growth from VRAYLAR and Lo LOESTRIN.
